%A Gozman,Leonid %A Perry,Kellie %A Nikogosov,Dimitri %A Klabukov,Ilya %A Shevlyakov,Artem %A Baranova,Ancha %D 2021 %J Frontiers in Genetics %C %F %G English %K COVID-19,Interferons,SARS-CoV-2,signaling,type I interferon,differential activity %Q %R 10.3389/fgene.2021.709388 %W %L %M %P %7 %8 2021-September-17 %9 Review %# %! Interferon genes in COVID-19 patients %* %< %T A Role of Variance in Interferon Genes to Disease Severity in COVID-19 Patients %U https://www.frontiersin.org/articles/10.3389/fgene.2021.709388 %V 12 %0 JOURNAL ARTICLE %@ 1664-8021 %X The rapid rise and global consequences of the novel coronavirus disease 19 (COVID-19) have again brought the focus of the scientific community on the possible host factors involved in patient response and outcome to exposure to the virus. The disease severity remains highly unpredictable, and individuals with none of the aforementioned risk factors may still develop severe COVID-19. It was shown that genotype-related factors like an ABO Blood Group affect COVID-19 severity, and the risk of infection with SARS-CoV-2 was higher for patients with blood type A and lower for patients with blood type O. Currently it is not clear which specific genes are associated with COVID-19 severity. The comparative analysis of COVID-19 and other viral infections allows us to predict that the variants within the interferon pathway genes may serve as markers of the magnitude of immune response to specific pathogens. In particular, various members of Class III interferons (lambda) are reviewed in detail.